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Vascular endothelial cells and neutrophils ynthesize and release potent vasodilatatory factors, i.e. endothelium-derived 
relaxing factors (EDRF) and neutrophil-derived relaxing factors (NDRF). One EDRF has been identified as nitric oxide 
(NO) derived from arginine. We studied the synthesis and release of NO from human neutrophils stimulated with the 
chemotactic peptide N-formyl-L-methionyl-L-leucyl-L-phenylalanine, platelet activating factor or leukotriene B4. The 
formation and release of NO was enhanced several-fold in the presence of superoxide dismutase, probably by inhibiting 
superoxide-induced breakdown of NO. The formation and release of NO but not the formation of superoxide anions 
was decreased in neutrophils pretreated with L-canavanine, an inhibitor of arginine-utilizing enzymes. Our data suggest 
that at least one NDRF is identical with NO or another labile NO containing compound derived from arginine. 
Nitric oxide; Neutrophil-derived relaxing factor; NADPH oxidase; Arginine; (Neutrophil, HL-60 cell) 
1. INTRODUCTION 
Vascular endothelial cells synthesize and release 
labile substances among prostacyclin which induce 
the relaxation of the adjacent vascular smooth 
muscle [l]. These substances have been termed 
EDRF, and at least one EDRF stimulates the solu- 
ble guanylate cyclase, which catalyzes the forma- 
tion of cyclic GMP, to a similar extent to nitric 
oxide (NO) containing compounds [2,3]. One 
EDRF was recently identified as NO or a labile NO 
containing compound derived from arginine [4-91. 
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The basal formation and release of endothelial NO 
is stimulated by bradykinin and ATP [4,9]. The 
biosynthesis of NO is inhibited by CAN, a struc- 
tural analogue of arginine and an inhibitor of 
various arginine-utilizing enzymes [9]. 
Rat peritoneal neutrophils induce vascular 
smooth muscle relaxation via the formation of 
NDRF which shows pharmacological and physico- 
chemical profiles similar to those of EDRF [ 10). In 
addition, various murine macrophage cell lines 
synthesize nitrite and nitrate derived from arginine 
upon exposure to E. coli lipopolysaccharide or 
interferon-v [ 11,121. These oxides of nitrogen have 
been suggested to play a central role in 
macrophage-induced cytotoxicity. We investigated 
the effects of various intercellular signal 
molecules, which stimulate NADPH oxidase- 
catalyzed 02 formation and other functions of 
neutrophils, on the formation and release of NO. 
We report here on formation and release of NO 
from human neutrophils and HL-60 cells differen- 
tiated by dbcAMP. 
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2. MATERIALS AND METHODS 
Neutrophils were obtained from heparinized venous blood of 
male healthy volunteers. The neutrophils were isolated by dex- 
tran sedimentation and centrifugation through Ficoll-Hypaque 
as described previously [I3]. Cell preparations consisted of 
more than 98% viable neutrophils. In some of the experiments, 
neutrophils were pretreated for 4 h with 2 mM CAN at 
18-20°C. HL-60 cells were grown in suspension culture as 
described recently [13,14]. To induce differentiation along the 
neutrophil pathway, HL-60 cells were cultured for 48 h in the 
presence of 0.2 mM dbcAMP [13]. To induce differentiation 
along the monocytic pathway, HL-60 cells were cultured for 
120 h in the presence of 10 nM 1,25(0H)~D~ [15]. 1,25(OH)~Ds 
was a kind gift from Drs H. Gutmann and U. Fischer of 
Hoffmann-La Roche, Base], Switzerland. 
To measure the release of NO, neutrophils (3 x 10’ cells) or 
HL-60 cells (2 x 10s cells) were placed into dialysis tubings (type 
20/32-Visking, Serva, Heidelberg, FRG) with an exclusion limit 
between 8 and 15 kDa. Cells in the dialysis tubings were peri- 
fused at a flow rate of 3.3 ml/min with a buffer containing 
138 mM NaCl, 6 mM KCl, 1 mM MgC12, 2 mM CaC12, 
5.5 mM glucose, 20 mM Hepes/NaOH, pH 7.4, at 37”C, 
equilibrated with air. The release of NO was determined as 
described recently [4,7,9]. Briefly, the perifusate was pumped 
into a 1 1 three-necked round bottom flask containing a degass- 
ed solution of KI (l%, w/v) in glacial acetic acid under reflux. 
NO was extracted from this reaction mixture by a constant 
oxygen-free nitrogen flow (25 l/h) from which a 1.5 l/h aliquot 
was drawn through an ice trap into an NO,-chemiluminescence 
analyzer (Bendix 8101 C, UPK, Bad Nauheim, FRG). When the 
background chemiluminescence signal was stable, FMLP, PAF 
or LTB4 (each 100 nM) were added to the perifusion buffer, 
followed by the addition of SOD (50 U/ml). In preliminary ex- 
periments, these concentrations of FMLP, PAF and LTB4 were 
found to be maximally effective to induce both the formation 
and release of NO and 02 (not shown). 
NADPH oxidase-catalyzed Or release from cells was 
monitored at 37°C by continuous measurement of fer- 
ricytochrome c reduction inhibitable by SOD [13,14]. LTB4 was 
a kind gift of Dr Beck of Hoechst AG, Frankfurt/Main, FRG. 
PAF was purchased from Sigma Chemie (Deisenhofen, FRG). 
Sources for other materials have been described elsewhere 
[8,9,13,14]. 
3. RESULTS 
Upon exposure of human neutrophils to the 
chemotactic peptide FMLP, a NO chemilumines- 
cence signal was detected and reached a plateau 
after about 30 min, indicating a steady-state for- 
mation and release of NO (fig.1). Upon addition 
of SOD, the NO chemiluminescence signal was 
potentiated until another steady state was reached 
after about 20 min. Changing to a buffer without 
added FMLP and SOD resulted in a rapid decline 
of the steady-state NO chemiluminescence signal 
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Fig.1. Time course of the detection of the release of NO from 
human neutrophils. Neutrophils (3 x lo7 cells) in a dialysing 
tube were perifused with a buffer equilibrated with air at 37°C. 
The release of NO into the perifusate was monitored by the 
chemiluminescence method described in section 2. FMLP 
(IO0 nM) and SOD (50 U/ml) were added to the buffer where 
indicated by arrows. At the end of the experiment he buffer 
containing FMLP and SOD was replaced by a buffer devoid of 
these agents. 
to a value identical with that prior to the addition 
of FMLP and SOD. These data indicate that 
FMLP induces formation and release of NO which 
is reversible. Control experiments without added 
cells revealed that the addition of FMLP or SOD 
to the buffer in the absence of neutrophils did not 
affect the NO chemiluminescence signal (not 
shown). 
Similar results to those with FMLP were obtain- 
ed with PAF and LTB4 (table 1). In the absence of 
these stimuli, no NO chemiluminescence signal or 
02 release was detected. FMLP stimulated both 
the formation and release of NO and 02. The 
release of 02 was about three orders of magnitude 
higher than that of NO. SOD potentiated the 
FMLP-induced NO chemiluminescence signal 
more than 3-fold. When neutrophils were 
pretreated with 2 mM CAN for 4 h, the FMLP- 
induced formation and release of NO in the 
absence and presence of SOD was virtually 
abolished or reduced by about 40%, respectively. 
In contrast, FMLP-induced 02 release was unaf- 
fected by CAN. PAF and LTB4 were much less ef- 
fective activators of the formation and release of 
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Table 1 4. DISCUSSION 
Formation and release of NO and Or from human neutrophils 
and differentiated HL-60 cells 
Cell type NO release 0: release 
(pm01 . min-’ . lo-’ (pm01 *min-’ . 
cells) cells) lo-’ 
-SOD +SOD - SOD 
Neutrophils 
None <OS <OS <so 
FMLP 20+4 71k27 16800 f 4700 
FMLP + CAN <OS** 45 + 24* 17200 f 2400 
PAF 7*035* 2 2300 k 1100 
LTB4 9zt2 24k 0 2200 f 900 
HL-60 (dbcAMP) 
None <OS <0.5 <so 
FMLP 2ztl 5k 2 7500 f 2100 
HL-60 (1,25(OH)zDs) 
None <0.5 <0.5 <50 
FMLP <0.5 <0.5 1700 + loo0 
The formation and release of NO and Or from human 
neutrophils and HL-60 cells was determined as described in 
section 2. HL-60 cells were differentiated along the neutrophil 
or monocytic pathways with dbcAMP or 1,25(OH)zDs, 
respectively. The formation and release of NO and Or was 
determined under basal conditions and after addition of FMLP, 
PAF or LTB4 (100 nM each). In the experiments for the 
determination of NO formation and release, SOD (50 U/ml) 
was added to the buffer after the NO chemiluminescence signal 
had reached a steady state. In some experiments, neutrophils 
were pretreated with 2 mM CAN for 4 h. Data shown represent 
the mean f SE of 3-5 experiments. Data with and without 
CAN-pretreatment were tested for difference by a paired one- 
tailed t-test. * p < 0.1; ** p < 0.05 
Human neutrophils and dbcAMP-differentiated 
HL-60 cells form and release NO upon stimulation 
with FMLP, PAF or LTB4. The FMLP-induced 
formation and release of NO from the neutrophils 
was inhibited by CAN, a structural analogue of 
arginine and an inhibitor of arginine-utilizing en- 
zymes [9,1 I]. The latter finding suggests that 
neutrophil-derived NO is synthesized from 
arginine as was recently shown for endothelium- 
derived NO [7,9] and macrophage-derived nitrite 
and nitrate [11,12]. CAN did not inhibit FMLP- 
induced 02 release from neutrophils, indicating 
that synthesis and/or release of NO and 02 are in- 
dependently regulated. Several dissociations bet- 
ween the regulation of the release of 02 and oxides 
of nitrogen have been reported for macrophages 
[ 111. The NO chemiluminescence signals from 
neutrophils and HL-60 cells were increased by 
SOD, an enzyme scavenging 02 anions by 
dismuting them to Hz02 and 02. 02 anions but 
not Hz02 or HzOz-derived radicals are involved in 
the degradation of EDRF [16]. These data suggest 
that SOD by scavenging 02 anions prevents the 
degradation of neutrophil-derived NO. 
both NO and 02 than was FMLP. As was the case 
for FMLP, the PAF- and LTB4-induced formation 
and release of NO was potentiated by SOD. 
Rimele et al. [lo] showed the relaxation of 
isolated rat aortic rings by rat peritoneal 
neutrophils. These neutrophils were obtained after 
intraperitoneal injection of oyster glycogen. Thus, 
it is likely that these cells were stimulated rather 
than resting. We found that resting human 
neutrophils obtained from the peripheral blood did 
not release detectable NO until exposure to ap- 
propriate stimuli. 
HL-60 cells differentiated along the neutrophil 
and monocytic pathways with dbcAMP or 
1,25(OH)~Ds, respectively, do not release NO and 
0: in the absence of FMLP. In the presence of 
FMLP, dbcAMP-differentiated cells released NO 
and 02 at rates which were about lo- and 2-fold 
lower, respectively, than in neutrophils. SOD 
potentiated the effect of FMLP on the formation 
and release of NO. Upon exposure to FMLP, 
HL-60 cells differentiated with 1,25(OH)zD3 
released 02 at rates which were more than 4-fold 
lower than those of dbcAMP-differentiated cells. 
However, 1,25(0H)zD3_differentiated HL-60 cells 
did not release NO. 
The effectiveness order of intercellular signal 
molecules to induce the release of NO from human 
neutrophils is in parallel with the one for 02 for- 
mation and release [17] indicating that the initial 
steps of the transmembrane signal transduction 
process are probably identical for either signal 
molecule. HL-60 cells differentiated with dbcAMP 
may represent a useful model system to study the 
mechanisms underlying the formation and release 
of NO as they show responses to FMLP 
qualitatively similar to neutrophils. Further studies 
will have to elucidate the function of human 
neutrophil-derived NO in vascular smooth muscle 
regulation and cytotoxicity. 
Other recent studies have demonstrated the for- 
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mation and release of oxides of nitrogen from 
macrophages [11,121, liver [ 181, muscular tissue 
[ 191 and the formation and release of relaxing fac- 
tors similar to EDRF from cerebellum [20], respec- 
tively. When this manuscript was in the final stage 
of preparation, Hibbs et al. [21] and Marletta et al. 
[22] reported that murine macrophages timulated 
with E. coli lipopolysaccharide also release NO. 
We suggest that NO synthesized and released 
from different cells represents a new inter- and in- 
tracellular signal molecule with soluble guanylate 
cyclase as the intracellular effector system. 
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